©2017 by D-Lab

About

Philippe Lambin

LAMBIN Philippe: Doctor of Medicine (MD, Université Catholique de Louvain, Belgium

Doctor of Sciences (Ph.D.), Specialist in Radiation-Oncology,

Professor of Radiation Oncology, University of Maastricht (The Netherlands)

Date of birth: 1961, Uccle, Belgium.

Status: Married, four children - three stepchildren.

SUMMARY: Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & ERC PoC grant laureate” from 2016 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 461 peer reviewed scientific papers (Hirsch Index: 64 scopus 24-04-2017, 87 Google scholar), co-inventor of more than 18 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 50 completed PhD’s (2 with cum laude).

Moreover, Prof. P. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 35 clinical trials). He has been also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, Eureca, Artforce, Radiate, Quick-Concept, Requite, BD2decide) including ImmunoSABR (6 millions €, a multicentric randomized trial in metastatic lung cancer comparing radiotherapy plus or minus immunotherapy) and the Marie Curie Training network PREDICT of which he is the initiator and the coordinator and two NIH grant (“Radiomics”) form the US. His main areas of interest are directed towards translational research in Radiation Biology with a specific focus on tumour hypoxia, functional imaging (Radiomics), lung and head and neck cancer. More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy and the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. The website he launched, www.predictcancer.org, with validated predictive models has had more than 20.000 visitors from more than 133 countries.

He is one of the inventors of “Distributed learning” a revolutionary Big Data approach for health care (watch the animation of a project he managed) and “Radiomics” (watch the animation).

Few years ago, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an international external review committee and was described as having a “world-leading position”. The reviewers added, “In large part, this is due to the inspirational leadership of Prof. P. Lambin who has done an outstanding job of building a world-class research program within a relatively short period of time” (see ERC-KNAW report, p28).

In February 2015, he stopped his function of CEO of MAASTRO clinic and in September 2017 he joined the University of Maastricht, to to launch the new Dpt of Precision Medicine ( The D-Lab and The M-Lab), dedicate his time to research, in particular his ERC advanced grant, teaching & supervision of his PhD students.

Disclosures:

Dr Philippe Lambin reports grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures, DualTpharma and ptTheragnostic. He received an advisor (SAB)/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV and Convert pharmaceuticals. Dr Lambin has (minority) shares in the company Oncoradiomics SA and Convert pharmaceuticals SA and is co-inventor of two patents on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito,  three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures.